Trevor Fetter - Jun 5, 2025 Form 3 Insider Report for Omada Health, Inc. (OMDA)

Role
Director
Signature
/s/ Nathan Salha, as Attorney-in-Fact for Trevor Fetter
Stock symbol
OMDA
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
3
Date filed
6/5/2025, 04:43 PM
Previous filing
Jul 31, 2024
Next filing
Jul 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FETTER TREVOR Director C/O OMADA HEALTH, INC., 500 SANSOME STREET, SUITE 200, SAN FRANCISCO /s/ Nathan Salha, as Attorney-in-Fact for Trevor Fetter 2025-06-05 0001205447

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OMDA Stock Option (Right to Buy) Jun 5, 2025 Common Stock 75K $8.28 Direct F1, F2
holding OMDA Stock Option (Right to Buy) Jun 5, 2025 Common Stock 26.7K $6.06 Direct F1, F2
holding OMDA Stock Option (Right to Buy) Jun 5, 2025 Common Stock 11.7K $5.94 Direct F1, F2
holding OMDA Stock Option (Right to Buy) Jun 5, 2025 Common Stock 16.7K $10.44 Direct F2, F3
holding OMDA Series D-1 Preferred Stock Jun 5, 2025 Common Stock 55.6K See footnote F4, F5
holding OMDA Series E Preferred Stock Jun 5, 2025 Common Stock 55.6K See footnote F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is fully vested and exercisable.
F2 Reflects a 1-for-3 reverse stock split of the Issuer's outstanding common stock effected on May 27, 2025.
F3 1/24th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date.
F4 Each share of Series D-1 Preferred Stock and Series E Preferred Stock is convertible into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering after giving effect to the 1-for-3 reverse split of the Issuer's common stock effected on May 27, 2025. These shares are reported in Table II above on an as-converted basis and have no expiration date.
F5 Shares held by a limited liability company of which the Reporting Person is the sole member.

Remarks:

Exhibit 24.1 - Power of Attorney